Philippe Lopes-Fernandes, Ipsen CBO
Exclusive: A year into his role, Ipsen's CBO is on a $3B mission to get the company 'back on the right track'
As a biopharma exec, Philippe Lopes-Fernandes had followed Ipsen’s $1.3 billion buyout of Clementia and what then-CEO David Meek called a “largely derisked” rare …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
